VCM
MLTX icon

Voleon Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Voleon Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.95M Sell
373,021
-126,078
-25% -$2.09M 0.15% 148
2025
Q4 		$6.58M Buy
499,099
+458,826
+1,139% +$5.41M 0.14% 161
2025
Q3 		$289K Buy
+40,273
New +$2.1M 0.01% 730

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Voleon Capital Management's MLTX Position: Q1 2026 in Review

Voleon Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 25% in Q1 2026, selling an estimated $2.09M and leaving 373,021 shares worth $6.95M. The position accounts for 0.15% of the portfolio, ranked #148.

Voleon Capital Management first reported a position in MLTX in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Voleon Capital Management held 373,021 shares of MoonLake Immunotherapeutics worth $6.95M as of Q1 2026.
  • Voleon Capital Management sold 126,078 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.09M.
  • MoonLake Immunotherapeutics made up 0.15% of Voleon Capital Management's portfolio in Q1 2026, its #148 holding.
  • Voleon Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.